重症呼吸道病毒感染并发/继发侵袭性真菌感染

摘要/Abstract

摘要： 呼吸道病毒感染是侵袭性真菌感染的独立危险因素，包括流感、SARS-CoV、MERS-CoV等冠状病毒感染在内的重症病毒感染，因其发病机制或者治疗导致的免疫功能异常而继发侵袭性真菌感染的发病率及病死率已引起临床关注。特别是近来在全球范围内爆发的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）导致的新型冠状病毒感染（COVID-19），并发/继发侵袭性真菌感染的报道日益增多。了解重症病毒感染继发侵袭性真菌感染的危险因素、免疫反应、发病机制、临床表现及诊断治疗现状，有助于选择最适的诊断和治疗方法，从而做出及时诊断和精准治疗，以显著改善患者预后，降低患者病死率。

关键词: 呼吸道病毒, 侵袭性真菌感染, 免疫反应, 诊断, 治疗

中图分类号:

R519

刘晓, 宋营改, 李若瑜. 重症呼吸道病毒感染并发/继发侵袭性真菌感染[J]. 中国真菌学杂志, 2021, 16(3): 211-216.

参考文献

[1] World Health Organization. Factsheet: Influenza (seasonal): Burden of disease.. https://www.who.int/influenza/surveillance_monitoring/bod/en/.
[2] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020, 395 (10223):507-513.
[3] 刘伟,李若瑜.对新型冠状病毒肺炎继发真菌感染的思考[J].微生物与感染,2020,15(1):58-61.
[4] 余进,刘伟,陈伟,等. 关于重症新型冠状病毒肺炎继发侵袭性真菌感染实验室诊治建议[J].中国真菌学杂志,2020,15(1):1-5.
[5] Vanderbeke L, Spriet I, Breynaert C, et al. Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment[J]. Curr Opin Infect Dis, 2018, 31 (6):1-9.
[6] Xu LR, Chen BJ, Wang FP, et al. A higher rate of pulmonary fungal infection in chronic obstructive pulmonary disease patients with influenza in a large tertiary hospital [J]. Respiration, 2019,98(5):391-400.
[7] Yu LD, Feng ZY, Wang XW, et al. Fungal spondylodiscitis in a patient recovered from H7N9 virus infection: a case study and a literature review of the differences between Candida and Aspergillus spondylodiscitis [J].J Zhejiang Univ Sci B, 2016,17(11):874-881.
[8] Menia NK, Sharma SP, Bansal R. Fungal retinitis following influenza virus type A (H1N1) infection [J]. Indian J Ophthalmol, 2019,67(9):1483-1484.
[9] 陈晓红,王庆,倪法禹,等. 危重症人感染H7N9禽流感继发肺隐球菌病一例[J]. 中华结核和呼吸杂志, 2016,39(7): 558-561.
[10] Hosseinnezhad A, Rapose A. Cryptococccal meningoencephalitis after H1N1 influenza [J]. BMJ Case Rep, 2012,2012: bcr1120115224. doi: 10.1136/bcr.11.2011.5224.
[11] Gupta A, Capoor MR, Gupta S, et al. Concomitant infections of influenza A H1N1 and disseminated cryptococcosis in an HIV seropositive patient[J]. J Lab Physicians, 2015,7(2): 134-136.
[12] Huang J, Li H, Lan C, et al. Concomitant severe influenza and cryptococcal infections: A case report and literature review [J]. Medicine (Baltimore), 2019,98(19):e15544.
[13] Burke J, Soubani AO. Influenza and Pneumocystis jirovecii pneumonia in an allogeneic hematopoietic stem cell transplantation recipient: Coinfection or superinfection [J] ?Transpl Infect Dis, 2018, 20(1). DOI: 10.1111/tid.12802.
[14] Franconi I, Monari C, Tutone M, et al. Pneumocystosis as a complication of H1N1 influenza infection in an HIV-positive patient on effective Cart[J]. Open Forum Infect Dis, 2019, 6(4):ofz105.
[15] Pulcini C, Hasseine L, Mondain V, et al. Possible pandemic HIN1 influenza complicated by Pneumocystis jirovecii pneumonia in an HIV-infected patient[J]. J Mycol Med, 2012,22(1):88-91.
[16] van Kampen JJ, Bielefeld-Buss AJ, Ott A, et al. Case report: oseltamivir-induced resistant pandemic influenza A (H1N1) virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia[J]. J Med Virol, 2013, 85(6):941-943.
[17] Hwang DM, Chamberlain DW, Poutanen SM, et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto[J]. Mod Pathol, 2005,18(1):1-10.
[18] 雷红, 匡铁吉, 梁艳, 等. SARS患者合并细菌和真菌感染的分析[J]. 临床检验杂志, 2004, 22(3):171-171.
[19] 吴礼襄, 萧正伦, 袁锦屏. 重症传染性非典型肺炎医院内感染的临床分析[J]. 新医学, 2004, 35(9):536-538.
[20] 余国华, 李丽, 向军, 等. 从SARS患者血清发现双相型深部真菌的报告[J]. 中国实验动物学报, 2005, 13(3):140-143.
[21] Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia [J]. Int J Infect Dis, 2014, 29: 301-306.
[22] Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission[J]. Lancet, 2013, 381(9885):2265-2272.
[23] Apostolopoulou A, Esquer Garrigos Z, Vijayvargiya P, et al. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: A systematic review of the literature[J]. Diagnostics (Basel), 2020, 10(10):807.
[24] Arastehfar A, Carvalho A, Nguyen MH, et al. COVID-19-Associated candidiasis (CAC): An underestimated complication in the absence of immunological predispositions[J]? J Fungi (Basel), 2020, 6(4):211.
[25] Mehta S, Pandey A. Rhino-Orbital mucormycosis associated with COVID-19[J]. Cureus, 2020, 12(9):e10726.
[26] Basso RP, Poester VR, Benelli JL, et al. COVID-19-associated histoplasmosis in an AIDS patient [J]. Mycopathologia, 2020:1-4. DOI: 10.1007/s11046-020-00505-1.
[27] Larzábal FJ, Vilela A, Brusca S, et al. Diagnóstico simultáneo y evolución favorable de infección por Pneumocystis jirovecii, SARS-COV-2 y HIV avanzada [Simultaneous diagnosis and favorable evolution of infection with Pneumocystis jirovecii, SARS-CoV-2 and advanced HIV\[J]. Medicina (B Aires),2020, 80 (5):554-556.
[28] Ventoulis I, Sarmourli T, Amoiridou P, et al. Bloodstream infection by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of Saccharomyces in the ICU[J]. J Fungi (Basel), 2020, 6(3):98.
[29] Chowdhary A, Tarai B, Singh A, et al. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April-July 2020[J]. Emerg Infect Dis, 2020, 26(11):2694-2696.
[30] Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study[J]. Lancet Respir Med, 2018, 6(10):782-792.
[31] Wang J, Yang Q, Zhang P, et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series[J]. Crit Care, 2020, 24(1):299.
[32] Antinori S, Bonazzetti C, Gubertini G, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia[J]? Autoimmun Rev, 2020, 19 (7):102564.
[33] Mao H, Liu Y, Sia SF, et al. Avian influenza virus directly infects human natural killer cells and inhibits cell activity[J]. Virol Sin, 2017, 32(2):122-129.
[34] Beer KD, Jackson BR, Chiller T, et al. Does pulmonary aspergillosis complicate coronavirus disease 2019[J]? Crit Care Explor, 2020, 2 (9):e0211.
[35] Nicolas de Lamballerie C, Pizzorno A, Fouret J, et al. Transcriptional profiling of immune and inflammatory responses in the context of SARS-CoV-2 fungal superinfection in a human airway epithelial model[J]. Microorganisms, 2020, 8(12):1974.
[36] Chen WW, Xie YX, Zhang YH, et al. Changes and analysis of peripheral white blood cells and lymphocyte subsets for patients with pandemic influenza A virus (H1N1) infection[J]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 2010, 24 (5):331-333.
[37] Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China[J]. N Engl J Med, 2009, 361(26):2507-2517.
[38] Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China[J]. J Infect, 2020, 80(4):388-393.
[39] White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU[J]. Clin Infect Dis, 2020:ciaa1298. DOI: 10.1093/cid/ciaa1298
[40] Mohamed A, Rogers TR, Talento AF. COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges[J]. J Fungi (Basel), 2020, 6(3):115.
[41] Immel S, Yu E. Case report: Disseminated aspergillosis complicating influenza[J]. Med Mycol Case Rep, 2019, 24: 65-68.
[42] Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium[J]. Clin Infect Dis, 2019,71(6):1367-1376.
[43] Verweij PE, Rijnders BJA, Brüggemann RJM, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion[J]. Intensive Care Med, 2020, 46 (8):1524-1535.
[44] Zhang H, Zhang Y, Wu J, et al. Risks and features of secondary infections in severe and critical ill COVID-19 patients[J]. Emerg Microbes Infect, 2020, 9(1):1958-1964.